insurers glp-1 coverage news The Access Gap: Mapping Who Can Actually Afford America's Miracle Weight-Loss Drugs Employers Drop GLP-1 Coverage Due

This helps slow down visible signs of aging and improves overall skin vitality

FOUNDAYO is a small-molecule, non-peptide GLP-1 receptor agonist

The treatment reduced periorbital wrinkles by 55%, outperforming placebo and vitamin K cream, with 70% of participants reporting improved firmness and clarity (Abdulghani et al., 1998)

In addition, the compound did not trigger the nausea, malaise and gastrointestinal adverse effects commonly seen with many first-generation GLP-1 therapies, a distinction that could become increasingly significant as patient populations and adherence demands grow

Side Effects and Safety Considerations Both peptides have relatively favorable safety profiles based on existing research and clinical use in Russia over several decades